Torii Pharmaceutical Co., Ltd. (TYO:4551)
Japan
· Delayed Price · Currency is JPY 4,395.00
-55.00 (-1.24%)
Mar 10, 2025, 3:30 PM JST
Torii Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 60,144 | 54,338 | 48,562 | 46,290 | 41,052 | Upgrade
|
| Other Revenue | 282 | 300 | 334 | 697 | 648 | Upgrade
|
| Revenue | 60,426 | 54,638 | 48,896 | 46,987 | 41,700 | Upgrade
|
| Revenue Growth (YoY) | 10.59% | 11.74% | 4.06% | 12.68% | -3.02% | Upgrade
|
| Cost of Revenue | 36,009 | 31,880 | 25,516 | 22,649 | 19,962 | Upgrade
|
| Gross Profit | 24,417 | 22,758 | 23,380 | 24,338 | 21,738 | Upgrade
|
| Selling, General & Admin | 14,592 | 14,014 | 15,944 | 18,591 | 16,165 | Upgrade
|
| Research & Development | 2,824 | 3,490 | 1,661 | 832 | 596 | Upgrade
|
| Operating Expenses | 17,618 | 17,722 | 17,839 | 19,682 | 16,999 | Upgrade
|
| Operating Income | 6,799 | 5,036 | 5,541 | 4,656 | 4,739 | Upgrade
|
| Interest & Investment Income | 463 | 399 | 312 | 280 | 274 | Upgrade
|
| Currency Exchange Gain (Loss) | -81 | -101 | -132 | -60 | -35 | Upgrade
|
| Other Non Operating Income (Expenses) | -257 | -28 | -184 | -30 | -8 | Upgrade
|
| EBT Excluding Unusual Items | 6,924 | 5,306 | 5,537 | 4,846 | 4,970 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 323 | 187 | -40 | - | Upgrade
|
| Asset Writedown | -200 | -36 | -2 | -37 | -9 | Upgrade
|
| Other Unusual Items | - | -1 | - | -3 | -737 | Upgrade
|
| Pretax Income | 6,724 | 5,592 | 5,722 | 4,766 | 4,224 | Upgrade
|
| Income Tax Expense | 1,682 | 1,473 | 1,778 | 1,392 | 729 | Upgrade
|
| Net Income | 5,042 | 4,119 | 3,944 | 3,374 | 3,495 | Upgrade
|
| Net Income to Common | 5,042 | 4,119 | 3,944 | 3,374 | 3,495 | Upgrade
|
| Net Income Growth | 22.41% | 4.44% | 16.89% | -3.46% | -87.23% | Upgrade
|
| Shares Outstanding (Basic) | 28 | 28 | 28 | 28 | 28 | Upgrade
|
| Shares Outstanding (Diluted) | 28 | 28 | 28 | 28 | 28 | Upgrade
|
| Shares Change (YoY) | 0.02% | 0.02% | 0.02% | 0.03% | 0.04% | Upgrade
|
| EPS (Basic) | 179.37 | 146.57 | 140.38 | 120.11 | 124.47 | Upgrade
|
| EPS (Diluted) | 179.37 | 146.57 | 140.38 | 120.11 | 124.46 | Upgrade
|
| EPS Growth | 22.38% | 4.41% | 16.87% | -3.49% | -87.23% | Upgrade
|
| Free Cash Flow | 3,487 | -3,285 | 2,300 | -306 | -3,736 | Upgrade
|
| Free Cash Flow Per Share | 124.05 | -116.89 | 81.86 | -10.89 | -133.04 | Upgrade
|
| Gross Margin | 40.41% | 41.65% | 47.82% | 51.80% | 52.13% | Upgrade
|
| Operating Margin | 11.25% | 9.22% | 11.33% | 9.91% | 11.36% | Upgrade
|
| Profit Margin | 8.34% | 7.54% | 8.07% | 7.18% | 8.38% | Upgrade
|
| Free Cash Flow Margin | 5.77% | -6.01% | 4.70% | -0.65% | -8.96% | Upgrade
|
| EBITDA | 7,207 | 5,495 | 5,995 | 5,069 | 5,321 | Upgrade
|
| EBITDA Margin | 11.93% | 10.06% | 12.26% | 10.79% | 12.76% | Upgrade
|
| D&A For EBITDA | 408 | 459 | 454 | 413 | 582 | Upgrade
|
| EBIT | 6,799 | 5,036 | 5,541 | 4,656 | 4,739 | Upgrade
|
| EBIT Margin | 11.25% | 9.22% | 11.33% | 9.91% | 11.36% | Upgrade
|
| Effective Tax Rate | 25.01% | 26.34% | 31.07% | 29.21% | 17.26% | Upgrade
|
| Advertising Expenses | 1,960 | 1,582 | 1,581 | 4,187 | 3,316 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.